Literature DB >> 18046586

Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure-activity relationship as a watchdog mechanism in experimental therapeutics and biology.

Júlio S Rebouças1, Ivan Spasojević, Ines Batinić-Haberle.   

Abstract

Superoxide is involved in a plethora of pathological and physiological processes via oxidative stress and/or signal transduction pathways. Superoxide dismutase (SOD) mimics have, thus, been actively sought for clinical and mechanistic purposes. Manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is one of the most intensely explored "SOD mimics" in biology and medicine. However, we show here that this claimed SOD activity of MnTBAP in aqueous media is not corroborated by comprehensive structure-activity relationship studies for a wide set of Mn porphyrins and that MnTBAP from usual commercial sources contains different amounts of noninnocent trace impurities (Mn clusters), which inhibited xanthine oxidase and had SOD activity in their own right. In addition, the preparation and thorough characterization of a high-purity MnTBAP is presented for the first time and confirmed that pure MnTBAP has no SOD activity in aqueous medium. These findings call for an assessment of the relevance and suitability of using MnTBAP (or its impurities) as a mechanistic probe and antioxidant therapeutic; conclusions on the physiological and pathological role of superoxide derived from studies using MnTBAP of uncertain purity should be examined judiciously. An unequivocal distinction between the biological effects due to MnTBAP and that of its impurities can only be unambiguously made if a pure sample is/was used. This work also illustrates the contribution of fundamental structure-activity relationship studies not only for drug design and optimization, but also as a "watchdog" mechanism for checking/spotting eventual incongruence of drug activity in chemical and biological settings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046586     DOI: 10.1007/s00775-007-0324-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  39 in total

1.  Functional mimics of superoxide dismutase enzymes as therapeutic agents.

Authors:  D P Riley
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  Manganese supplementation relieves the phenotypic deficits seen in superoxide-dismutase-null Escherichia coli.

Authors:  May Al-Maghrebi; Irwin Fridovich; Ludmil Benov
Journal:  Arch Biochem Biophys       Date:  2002-06-01       Impact factor: 4.013

3.  Kinetic properties of Cu,Zn-superoxide dismutase as a function of metal content--order restored.

Authors:  Sara Goldstein; Irwin Fridovich; Gidon Czapski
Journal:  Free Radic Biol Med       Date:  2006-06-03       Impact factor: 7.376

4.  An alternative Ca2+-dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics.

Authors:  Joseph S Tauskela; Eric Brunette; Natasha O'Reilly; Geoff Mealing; Tanya Comas; Tania F Gendron; Robert Monette; Paul Morley
Journal:  FASEB J       Date:  2005-08-04       Impact factor: 5.191

5.  Mn porphyrin-based superoxide dismutase (SOD) mimic, MnIIITE-2-PyP5+, targets mouse heart mitochondria.

Authors:  Ivan Spasojević; Yumin Chen; Teresa J Noel; Yiqun Yu; Marsha P Cole; Lichun Zhang; Yunfeng Zhao; Daret K St Clair; Ines Batinić-Haberle
Journal:  Free Radic Biol Med       Date:  2007-01-13       Impact factor: 7.376

6.  Control of redox transitions and oxygen species binding in Mn centers by biologically significant ligands; model studies with [Mn]-bacteriochlorophyll a.

Authors:  Idan Ashur; Alex Brandis; Moshe Greenwald; Yahel Vakrat-Haglili; Varda Rosenbach-Belkin; Hugo Scheer; Avigdor Scherz
Journal:  J Am Chem Soc       Date:  2003-07-23       Impact factor: 15.419

Review 7.  Peroxynitrite: biochemistry, pathophysiology and development of therapeutics.

Authors:  Csaba Szabó; Harry Ischiropoulos; Rafael Radi
Journal:  Nat Rev Drug Discov       Date:  2007-08       Impact factor: 84.694

Review 8.  Therapeutic potential of superoxide dismutase mimetics as therapeutic agents in critical care medicine.

Authors:  Daniela Salvemini; Salvatore Cuzzocrea
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

9.  A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro.

Authors:  B J Day; S Shawen; S I Liochev; J D Crapo
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

Review 10.  Superoxide anion: oncogenic reactive oxygen species?

Authors:  Shazib Pervaiz; Marie-Veronique Clement
Journal:  Int J Biochem Cell Biol       Date:  2007-04-21       Impact factor: 5.085

View more
  37 in total

1.  A new method for the quantification of superoxide dismutase mimics with an allopurinol-xanthine oxidase-lucigenin enhanced system.

Authors:  Bogdan Alexandru Stoica; Gabriela Bordeianu; Raluca Stanescu; Dragomir N Serban; Mihai Nechifor
Journal:  J Biol Inorg Chem       Date:  2011-04-23       Impact factor: 3.358

Review 2.  Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.

Authors:  Ines Batinic-Haberle; Ivan Spasojevic; Hubert M Tse; Artak Tovmasyan; Zrinka Rajic; Daret K St Clair; Zeljko Vujaskovic; Mark W Dewhirst; Jon D Piganelli
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

3.  Determination of residual manganese in Mn porphyrin-based superoxide dismutase (SOD) and peroxynitrite reductase mimics.

Authors:  Júlio S Rebouças; Ivan Kos; Zeljko Vujasković; Ines Batinić-Haberle
Journal:  J Pharm Biomed Anal       Date:  2009-07-09       Impact factor: 3.935

4.  Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes.

Authors:  Júlio S Rebouças; Ivan Spasojević; Ines Batinić-Haberle
Journal:  J Pharm Biomed Anal       Date:  2008-08-14       Impact factor: 3.935

5.  The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies.

Authors:  Kristy Lee; Margaret M Briehl; Andrew P Mazar; Ines Batinic-Haberle; Julio S Reboucas; Betty Glinsmann-Gibson; Lisa M Rimsza; Margaret E Tome
Journal:  Free Radic Biol Med       Date:  2013-02-14       Impact factor: 7.376

6.  Mn porphyrin-based SOD mimic, MnTnHex-2-PyP(5+), and non-SOD mimic, MnTBAP(3-), suppressed rat spinal cord ischemia/reperfusion injury via NF-κB pathways.

Authors:  T Celic; J Španjol; M Bobinac; A Tovmasyan; I Vukelic; J S Reboucas; I Batinic-Haberle; D Bobinac
Journal:  Free Radic Res       Date:  2014-10-10

Review 7.  Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.

Authors:  Ines Batinic-Haberle; Zrinka Rajic; Artak Tovmasyan; Julio S Reboucas; Xiaodong Ye; Kam W Leong; Mark W Dewhirst; Zeljko Vujaskovic; Ludmil Benov; Ivan Spasojevic
Journal:  Free Radic Biol Med       Date:  2011-05-06       Impact factor: 7.376

8.  Impact of electrostatics in redox modulation of oxidative stress by Mn porphyrins: protection of SOD-deficient Escherichia coli via alternative mechanism where Mn porphyrin acts as a Mn carrier.

Authors:  Júlio S Rebouças; Gilson DeFreitas-Silva; Ivan Spasojević; Ynara M Idemori; Ludmil Benov; Ines Batinić-Haberle
Journal:  Free Radic Biol Med       Date:  2008-05-05       Impact factor: 7.376

9.  Lipophilicity is a critical parameter that dominates the efficacy of metalloporphyrins in blocking the development of morphine antinociceptive tolerance through peroxynitrite-mediated pathways.

Authors:  Ines Batinić-Haberle; Michael M Ndengele; Salvatore Cuzzocrea; Júlio S Rebouças; Ivan Spasojević; Daniela Salvemini
Journal:  Free Radic Biol Med       Date:  2008-10-17       Impact factor: 7.376

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.